248 related articles for article (PubMed ID: 24494798)
1. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease.
Su Z; Wang X; Gao X; Liu Y; Pan C; Hu H; Beyer RP; Shi M; Zhou J; Zhang J; Serra AL; Wüthrich RP; Mei C
J Intern Med; 2014 Nov; 276(5):470-85. PubMed ID: 24494798
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κB-induced inflammation.
Wu M; Gu J; Mei S; Xu D; Jing Y; Yao Q; Chen M; Yang M; Chen S; Yang B; Qi N; Hu H; Wüthrich RP; Mei C
Nephrol Dial Transplant; 2016 Nov; 31(11):1826-1834. PubMed ID: 27190325
[TBL] [Abstract][Full Text] [Related]
4. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
5. The C-terminal tail of polycystin-1 regulates complement factor B expression by signal transducer and activator of transcription 1.
Wu M; Chen M; Jing Y; Gu J; Mei S; Yao Q; Zhou J; Yang M; Sun L; Wang W; Hu H; Wüthrich RP; Mei C
Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1284-94. PubMed ID: 26984954
[TBL] [Abstract][Full Text] [Related]
6. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Nagao S; Yamaguchi T; Kusaka M; Maser RL; Takahashi H; Cowley BD; Grantham JJ
Kidney Int; 2003 Feb; 63(2):427-37. PubMed ID: 12631108
[TBL] [Abstract][Full Text] [Related]
7. Altered Hippo signalling in polycystic kidney disease.
Happé H; van der Wal AM; Leonhard WN; Kunnen SJ; Breuning MH; de Heer E; Peters DJ
J Pathol; 2011 May; 224(1):133-42. PubMed ID: 21381034
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor pathway in rats with autosomal dominant polycystic kidney disease.
Nagao S; Kusaka M; Nishii K; Marunouchi T; Kurahashi H; Takahashi H; Grantham J
J Am Soc Nephrol; 2005 Jul; 16(7):2052-62. PubMed ID: 15888569
[TBL] [Abstract][Full Text] [Related]
9. Expression of Na+/H+ exchanger regulatory factor 1 in autosomal-dominant polycystic kidney disease.
Wang JQ; Qin F; Zhu L
J Int Med Res; 2015 Oct; 43(5):629-38. PubMed ID: 26142394
[TBL] [Abstract][Full Text] [Related]
10. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.
Chang MY; Parker E; Ibrahim S; Shortland JR; Nahas ME; Haylor JL; Ong AC
Nephrol Dial Transplant; 2006 Aug; 21(8):2078-84. PubMed ID: 16720597
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial Abnormality Facilitates Cyst Formation in Autosomal Dominant Polycystic Kidney Disease.
Ishimoto Y; Inagi R; Yoshihara D; Kugita M; Nagao S; Shimizu A; Takeda N; Wake M; Honda K; Zhou J; Nangaku M
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993480
[TBL] [Abstract][Full Text] [Related]
12. Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
Liu C; Li H; Gao X; Yang M; Yuan L; Fu L; Wang X; Mei C
Am J Physiol Renal Physiol; 2018 May; 314(5):F844-F854. PubMed ID: 26911848
[TBL] [Abstract][Full Text] [Related]
13. Altered ATP-sensitive P2 receptor subtype expression in the Han:SPRD cy/+ rat, a model of autosomal dominant polycystic kidney disease.
Turner CM; Ramesh B; Srai SK; Burnstock G; Unwin RJ
Cells Tissues Organs; 2004; 178(3):168-79. PubMed ID: 15655334
[TBL] [Abstract][Full Text] [Related]
14. Reduced decay-accelerating factor expression promotes complement-mediated cystogenesis in murine ADPKD.
Bin S; Yoo M; Molinari P; Gentile M; Budge K; Cantarelli C; Khan Y; La Manna G; Baldwin WM; Dvorina N; Cravedi P; Gusella GL
JCI Insight; 2024 May; 9(12):. PubMed ID: 38912583
[TBL] [Abstract][Full Text] [Related]
15. Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease.
Salih M; Demmers JA; Bezstarosti K; Leonhard WN; Losekoot M; van Kooten C; Gansevoort RT; Peters DJ; Zietse R; Hoorn EJ;
J Am Soc Nephrol; 2016 Oct; 27(10):3079-3092. PubMed ID: 26940098
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.
Jamadar A; Suma SM; Mathew S; Fields TA; Wallace DP; Calvet JP; Rao R
Cell Death Dis; 2021 Oct; 12(10):947. PubMed ID: 34650051
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-β inhibits cystogenesis in human autosomal dominant polycystic kidney epithelial cells.
Elberg D; Jayaraman S; Turman MA; Elberg G
Exp Cell Res; 2012 Aug; 318(13):1508-16. PubMed ID: 22504005
[TBL] [Abstract][Full Text] [Related]
18. Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease.
Hassane S; Leonhard WN; van der Wal A; Hawinkels LJ; Lantinga-van Leeuwen IS; ten Dijke P; Breuning MH; de Heer E; Peters DJ
J Pathol; 2010 Sep; 222(1):21-31. PubMed ID: 20549648
[TBL] [Abstract][Full Text] [Related]
19. Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats.
Cowley BD; Ricardo SD; Nagao S; Diamond JR
Kidney Int; 2001 Dec; 60(6):2087-96. PubMed ID: 11737583
[TBL] [Abstract][Full Text] [Related]
20. CD8
Kleczko EK; Marsh KH; Tyler LC; Furgeson SB; Bullock BL; Altmann CJ; Miyazaki M; Gitomer BY; Harris PC; Weiser-Evans MCM; Chonchol MB; Clambey ET; Nemenoff RA; Hopp K
Kidney Int; 2018 Dec; 94(6):1127-1140. PubMed ID: 30249452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
